HRT Financial’s Aurinia Pharmaceuticals AUPH Stock Holding History

HRT Financial’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.13M	Buy	211,025 +128,791	+157%	+$1.88M	0.01%	1290
2025 Q4	$1.31M	Buy	82,234 +41,394	+101%	+$587K	﹤0.01%	1560
2025 Q3	$451K	Buy	+40,840	New	+$446K	﹤0.01%	1948
2024 Q1	–	Sell	-30,761	Closed	-$276K	–	2300
2023 Q4	$276K	Sell	30,761 -3,775	-11%	-$31.1K	﹤0.01%	1655
2023 Q3	$268K	Sell	34,536 -70,687	-67%	-$691K	﹤0.01%	1713
2023 Q2	$1.02M	Buy	105,223 +15,158	+17%	+$157K	0.01%	941
2023 Q1	$987K	Buy	+90,065	New	+$793K	0.01%	955
2022 Q2	–	Sell	-38,755	Closed	-$479K	–	2910
2022 Q1	$479K	Buy	+38,755	New	+$599K	﹤0.01%	1873
2021 Q3	–	Sell	-96,892	Closed	-$1.25M	–	3263
2021 Q2	$1.25M	Buy	+96,892	New	+$1.23M	0.01%	881

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HRT Financial's AUPH Position: Q1 2026 in Review

HRT Financial increased its Aurinia Pharmaceuticals (AUPH) stake by 157% in Q1 2026, buying an estimated $1.88M and bringing the position to 211,025 shares worth $3.13M. The position accounts for 0.01% of the portfolio, ranked #1290.

HRT Financial first reported a position in AUPH in Q2 2021 and has held it in 9 quarters since. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

HRT Financial held 211,025 shares of Aurinia Pharmaceuticals worth $3.13M as of Q1 2026.
HRT Financial bought 128,791 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $1.88M.
Aurinia Pharmaceuticals made up 0.01% of HRT Financial's portfolio in Q1 2026, its #1290 holding.
HRT Financial first reported a position in Aurinia Pharmaceuticals in Q2 2021 and has held it in 9 quarters since.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.